Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

TREND: A phase IIIb, randomized, a 12-month, Visual Acuity assessor-masked, interventional study assessing the efficacy and safety of the Treat and Extend vs monthly regimens of 0.5 mg ranibizumab in patients with newly diagnosed nAMD
19/03/2014

Foto3

 

TREND Study: a 12-month, phase IIIb, randomized, Visual Acuity assessor-masked, multi-center, interventional study assessing the efficacy and safety of the Treat and Extend vs monthly regimens of 0.5 mg ranibizumab intravitreal (IVT) injections in patients with newly diagnosed nAMD. Patients will be randomized 1:1 into one of two treatment arms, Treat and Extend or monthly regimens.

Description

The Study aims to demonstrate that the efficacy and safety of ranibizumab (0.5mm) in a Treat-and-Extend protocol is no less than the monthly injection protocol for the treatment of age-related macular degeneration (AMD) of a wet or exudative type.

Up to now, the medicine Lucentis has been presented in a vial and has required filling. In this trial, for the first time in Spain, Lucentis is provided in a pre-filled syringe.

If you are interested in taking part in a clinical trial, please call us at 935 950 155 and we will assess whether you are eligible. Further information at clinicals trials.

Injections intravitréennesDMLA exsudative ou humide

Author

Dr Jordi Monés, médecin, titulaire d’un doctorat
Inscrit à l'ordre des médecins de Barcelone, sous le numéro 22838
Directeur
Docteur en médecine et chirurgie
Spécialiste en ophtalmologie
Spécialiste de la rétine, de la macula et du vitré

Last modified: 16 September, 2019 - 12:24